JavaScript is disabled. Please enable to continue!
Services >> Cell Based Phenotypic >> Anti-Infectives

In vitro phenotypic – Anti-Infectives

Sidebar Image

With the rising prevalence of drug-resistant microorganisms, effective and potent anti-infective agents are becoming increasingly more important in Drug Discovery programs as requirements to treat infectious diseases. Eurofins Pharma Discovery Services, leverages the >30 years of expertise of our Eurofins Panlabs Taiwan team,  to provide a robust portfolio of in vitro anti-infective models to support the discovery and development of novel antimicrobial therapies.

Our in vitro portfolio follows the Clinical and Laboratory Standards Institute (CLSI) methods in order to evaluate the antimicrobial activity of your test agents. Our services have  broad flexibility, allowing for combination testing, determining synergistic, indifferent, or antagonistic effects, as well as resistance analysis to determine the rate at which organisms develop a non-susceptible phenotype which can have major clinical implications.

Using a comprehensive collection of > 500 clinically relevant Gram-positive and Gram-negative bacteria (including multi-drug resistant, MDR, organisms), anaerobic bacteria, yeast, and filamentous fungi, our team provides the support and experience that your anti-infective drug program needs to succeed.

Features of in vitro anti-infective services from Eurofins:

    • Determination of minimum inhibitory concentration (MIC)
      • Minimum Bactericidal Concentration (MBC)
      • Antibiotic susceptible organisms
      • MDR organisms, clinically relevant resistant mechanisms
      • Effect of human and/or mouse serum
      • Accelerated, one-week turnaround time is available
      • High volume compound testing
    • Panels for accelerated MIC testing
      • Bacterial broad spectrum screen
      • Fungal broad spectrum screen
      • Neisseria gonorrhoeae - MDR and susceptible strains
    • Time-kill analysis to identify bactericidal properties
    • Combination testing to determine synergistic, indifferent or antagonistic effects
    • Resistance analysis to determine the rate at which organisms develop a non-susceptible phenotype
    • Membrane lysis - bacteria and red blood cells
    • Clostridium difficile toxin - cytotoxicity and toxin neutralization
    • >500 pathogens, including:
      • Anaerobic bacteria: P. vulgaris
      • Fungi: C. albicans, A. fumigatus
      • Gram-negative bacteria: A. baumannii, E. coli, K. pneumoniae, N. gonorrhoeae, P. aeruginosa
      • Gram-positive bacteria: E. faecalis, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes

Anti-infective in vivo services:

  • Companion in vivo services for preclinical anti-microbial assessment are provided by our Partner Lab Pharmacology Discovery Services